



**The University of Western Ontario
Biohazards Subcommittee Meeting**

Minutes of February 15th 2011
10:00 a.m. – 11:30 a.m., SSB 5104

Present: Dr. J. Millar (Chair), Dr. S. Koval, Dr. T. deLangley, Ron Noseworthy (for Dr. G. Dekaban), J. Stanley, E. Gray (OH&S Intern)

Regrets: Dr. S. Barr, Dr. G. Dekaban, Dr. S. Siu

1.0 Introductions

None needed.

2.0 Approval of Minutes – January 14th, 2011

Approved: No issues.

3.0 Biological Agents Registry Forms

3.1 Hamilton, D.W. (Re-visit)

Tabled: The committee found the form difficult to read. There are many spelling errors in the use of biological agents section. Section 1.1 is incomplete. 'No' should be checked in sections that apply. The form should be sent back and asked to be typed so that it is legible

3.2 Possmayer, F.

Tabled: Section 2.2 should be 'no'. The containment level in section 2.3 needs to be clarified. Changes that result need to be stated in sections 4.2 and 4.3. The committee is unclear of the virus he is referring to in section 4.5.

3.3 Rogan, P. (Modification only)

Approved: No issues.

3.4 O’Gorman, D. and Gan, B.S.

Approved: The form should be updated electronically so it no longer includes the lentivirus work. He will do a modification form when that work will begin. Table 3.2 is unknown. Section 4.2 should mention E. coli.

3.5 Grbic, M.

Approved: Section 14.3 should state the procedure in case of a needle stick injury.

3.6 Belliveau, D. (Re-visit)

Approved: No issues.

3.7 Menon, R. (Update)

Approved: No issues.

3.8 Fraser, D.

Tabled: The committee would like clarification of what the numbers mean in the research summary (they may be references that we don’t have). The committee would also like clarification of the date of the last Biosafety inspection for Robarts room 4.01.

3.9 Peters, T.

Approved: The tissue from surgery will be put in a leak proof container and into a leak proof bag. The Robarts imaging document needs to be followed.

3.10 Reider, M.

Approved: The full name of C. difficile should be listed in section 1. The E. coli strain they are working with is not pathogenic. It is unclear how much they will be culturing and where the work with C. difficile is being done off campus.

3.11 Strong, M. (Modification only)

Approved: No issues.

3.12 Staples, J.

Approved: Section 7.2 should be ‘yes’. Section 7.1 should be ‘yes’. The covering letter is excellent.

3.13 Gilles, E.

Approved: Section 4.4 should reflect that fact that she is using HeLa cells.

3.14 Wagner, G.

Tabled: There are no personnel listed. A signature is needed in section 12. The tracking comments must be removed from the document.

3.15 Hardy, D.

Approved: Table 2.2 should be 'no'. Section 14.2 needs to be completed. Table 2.3 should state 'no' where applicable.

3.16 Margaritis, A. (Re-visit)

Tabled: This form should be typed. There are no MSDS' for Saccharomyces.

3.17 Gloor, G. (Modification only)

Approved: No issues.

3.18 Khan, Z. (Re-visit)

Approved: Dr. T. deLangley approved the form based on the animal side. The committee would like input from Dr. Dekaban and Dr. Barr because of the lentiviral work. Notes from Dr. Dekaban: Unclear of where the primary bovine endothelial cells are coming from. Section 4.1 should be 'no' and section 4.2 should be 'yes'. Section 4.3 should be 'no' and section 6.4 should be 'yes'. Clarify that no virus is used and indicate that if virus will be used a modification form should be completed.

3.19 Goldberg, H. (Re-visit)

Tabled: The form should be sent back and asked for a one page research summary. Section 4.4 should be updated to reflect the use of HEK cells. 'No' should be stated where applicable in Table 2.3.

3.20 McLachlin, D.

Approved: Agents in teaching protocol were very well done.

3.21 Hess, D. (Modification only)

Approved: No issues.

3.22 Feng, Q**(Re-visit)**

Tabled: The committee is unclear of what 2.5×10^7 clones / g of E.coli bacteria is. In section 1.2 the E.coli he has listed is level 2 not level 2+. Section 4.4 should be updated to reflect his use of HEK cells. In section 6.0 the form states that they will be injecting lentivirus into live animals as well as cells. This needs to be confirmed. Input from Dr. Dekaban is required. Dr. Dekaban's comments: Containment level should be handled as per Rugar in Level 3 if the virus is being directly injected into the heart. This is to be done in the hood. Viral shedding is also an issue so they should have Biosafety cages. For the injection of transduced fibroblasts, it is unclear how many culture passages there are before injection. The virus policy applies and animal work should be level 2. Dr. Siu should contact them regarding the Workplace Health Lentiviral Policy.

3.23 Deroo, B.**(Re-visit)**

Tabled: Section 4.4 needs to be updated to reflect the use of HEK cells. The toxin use amounts are still unclear.

3.24 Singh, B.**(Re-visit)**

Approved: All issues have been resolved other than the toxin dose issue. The toxin will need to be stored in at least two different locations.

3.25 Reid, G.**(Re-visit)**

Tabled: The committee did not have time to review.

3.26 Gunaratnam, L.**(Modification only)**

Tabled: The committee did not have time to review.

Last Minute Additions

Tabled: The Committee did not have time to review items 3.27 – 3.31.

3.27 Shepherd, T.**(Re-visit)****3.28 Dixon, S.J.****3.29 Torchia, J.****(Re-visit)****3.30 Noble, E.****3.31 Lewis, J., Veldhuizen R. and Yamashita, Y.****3.32 Others?****4.0 Biotron Level 3 Update**

The Biotron Level 3 facility will not be used this Spring due to financial constraints.

5.0 Medical Surveillance Update for Level 3

There is no update from Dr. Siu at this time.

6.0 Update on Dr. P. Krishna Project (Ag Canada)

Dr. Millar suggested J. Stanley contact Dr. G. Thorn as he may know something about this type of work.

7.0 Biological Agents Registry Form: Update

Change the section on the form that says "Course Code" to "Course Name". Indicate on the form that it should be typed. Bold and capitalize the idea that the committee would like to see only one page for their research summary.

8.0 Other Business

8.1 Dr. J. Millar's Meeting with Dr. T. Hewitt.

Dr. Millar informed the committee there Dr. Hewitt has no concerns with how the committee is operating.

9.0 Adjournment

Meeting adjourned at 11:40 am.